Pro DEX free cash flow PDEX
Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.
- Last 12 months, to Sep 30, 2026
- $10.7M
- Latest quarter, Q1 FY27
- $6.1M
- +178% on a year earlier
- Fiscal year 2026
- $6.8M
Pro DEX's free cash flow was $10.7M over the twelve months to Sep 30, 2026.
In its latest quarter, Q1 FY27, it was $6.1M, up 178% on the same quarter a year before.
Over the five fiscal years to FY2026 it grew 28% a year on average.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2026 | $6.8M | n/a |
| FY2025 | −$2.9M | n/a |
| FY2022 | −$2.5M | n/a |
| FY2021 | −$3.8M | −187% |
| FY2020 | $4.4M | +128% |
| FY2019 | $1.9M | −11% |
| FY2018 | $2.2M | −17% |
| FY2017 | $2.6M | n/a |
| FY2016 | n/a | n/a |
| FY2015 | −$1M | n/a |
| FY2014 | n/a | n/a |
| FY2013 | −$1.4M | n/a |
| FY2012 | −$296K | −111% |
| FY2011 | $2.6M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | $6.1M | +178% | $10.7M | |
| Q4 FY26 | −$476K | n/a | $6.8M | |
| Q3 FY26 | $1.5M | +165% | $7M | |
| Q2 FY26 | $3.5M | n/a | $6M | |
| Q1 FY26 | $2.2M | +52% | −$2.2M | |
| Q4 FY25 | −$266K | n/a | −$2.9M | |
| Q3 FY25 | $574K | −86% | n/a | |
| Q2 FY25 | −$4.7M | −6194% | n/a | |
| Q1 FY25 | $1.5M | +447% | n/a | |
| Q3 FY24 | $4M | +80% | n/a | |
| Q2 FY24 | $77K | n/a | n/a | |
| Q1 FY24 | $266K | −90% | n/a |
Against its peers
Companies in Medical - Instruments & Supplies nearest Pro DEX's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| PDEXPro DEX | 5.8% |
| UTMDUtah Medical Products | 5.1% |
| INFUInfuSystem | 8.3% |
| EMBCEmbecta | n/m |
| KEQUKewaunee Scientific | 11.3% |
| TCMDTactile Systems Technology | 5.2% |
| APTAlpha Pro Tech | 10.4% |
| MOVMovado | 10.1% |
| NEPHNephros | n/m |
| IRMDIradimed | 2.6% |
| IARTIntegra Lifesciences | 8.1% |
| Peer median | 8.2% |
Where Pro DEX ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Pro DEX
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.